
    
      This is an open-label, single-arm study to evaluate the safety and efficacy of bilateral
      subretinal administration of voretigene neparvovec in Japanese patients with biallelic RPE65
      mutation-associated retinal dystrophy. Assessments will include full-field light sensitivity
      threshold testing, visual fields, visual acuity, vector shedding, immunogenicity and adverse
      events. Participants will be monitored for 5 years after treatment.
    
  